Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia

Background: Fluoropyrimidine toxicity is often due to variations in the gene (DPYD) encoding dihydropyrimidine dehydrogenase (DPD). DPYD genotyping can be used to adjust doses to reduce the likelihood of fluoropyrimidine toxicity while maintaining therapeutically effective drug levels. Methods: A mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Angela, Anderson, Helen, Hughesman, Curtis, Young, Sean, Lohrisch, Caroline, Ross, Colin J. D., Carleton, Bruce C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515725/
https://www.ncbi.nlm.nih.gov/pubmed/37745065
http://dx.doi.org/10.3389/fphar.2023.1257745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10515725/
https://www.ncbi.nlm.nih.gov/pubmed/37745065
http://dx.doi.org/10.3389/fphar.2023.1257745

Ejemplares similares